The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting
Source abstract
Abstract
Chemotherapy is a popular treatment approach against cancer but significant uptake of drugs by normal tissues is still a major limitation. Magnetic drug targeting (MDT) has been used to improve localized drug delivery to interstitial tumor targets. MDT is now being developed to improve drug delivery to tumor vessels. We thus seek to understand the role of magnetite (MAG-C) in drug loading, influence on cytotoxicity and vascular targeting characteristics. The inclusion of MAG-C at lower concentrations (0.5 mg/ml) in cationic liposomes did not alter the efficiency of loading etoposide, but at higher concentrations (2.5 mg/ml) incorporation decreased from 80+/-3.4% to 44+/-4.26%. MAG-C reduced the incorporation of dacarbazine. The incorporation was significantly lower compared to liposomal etoposide, both in the presence and absence of MAG-C. The incorporation efficiency of vinblastine sulfate in cationic liposomes was similar for low and relatively high MAG-C content; values for incorporation were 21+/-0.11 and 23+/-2, respectively. Polyethylene-glycol improved the efficiency of loading chemotherapeutic agents regardless of drug type. Additionally, cytotoxicity and tumor vascular targeting characteristics of liposome therapeutics were not influenced by MAG-C. The components used to prepare magnetic liposomes for MDT should be optimized for maximum therapeutic benefit.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Educational Methods and Media Use · English Language Learning and Teaching · Linguistics and Language Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Magnetic drug targeting: biodistribution and dependency on magnetic field strength10.1016/S0304-8853(02)00605-4 ↗
2. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies10.1007/s11095-005-2496-8 ↗
3. Locoregional cancer treatment with magnetic drug targeting
4. Magnetic drug targeting—biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment10.3109/1061186031000150791 ↗
5. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents10.1016/S1054-3589(08)60246-X ↗
6. Physiological aspects in magnetic drug-targeting10.1016/S0304-8853(98)00574-5 ↗
7. Targeted gene delivery to human osteocarcinoma cells with magnetic cationic liposomes under a magnetic field
8. Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microsperes10.3109/10611869308998759 ↗
9. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters
10. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet10.1002/ijc.20035 ↗
11. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility10.1148/radiol.2392042110 ↗
12. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes10.1097/00008390-200304000-00004 ↗
13. The effect of RGD peptide-conjugated magnetite cationic liposomes on cell growth and cell sheet harvesting10.1016/j.biomaterials.2005.03.039 ↗
14. The role of angiogenesis in tumor growth
15. Vascularization of tumors; a review10.1007/BF00409698 ↗
16. Vascular targeting agents as cancer therapeutics10.1158/1078-0432.CCR-0642-03 ↗
17. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model10.1046/j.1523-1747.2003.12057.x ↗
18. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature10.1002/ijc.20083 ↗
19. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice10.1172/JCI965 ↗
20. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors
21. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo10.1200/JCO.2004.11.070 ↗
22. Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma10.1200/JCO.1999.17.9.2745 ↗
23. Inhibition of tubulin-microtubule polymerization by drugs of the vinka alkaloid class
24. The binding of vincristine, vinblastine and colchicine to tubulin10.1016/0006-291X(72)90546-3 ↗
25. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine10.1021/bi953037i ↗
26. Etoposide: four decades of development of a topoisomerase II inhibitor10.1016/S0959-8049(98)00228-7 ↗
27. Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes10.1074/jbc.271.46.29238 ↗
28. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy10.1073/pnas.88.24.11460 ↗
29. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature10.1016/j.bbamem.2006.10.006 ↗
30. Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties10.1016/S0005-2736(01)00290-5 ↗
31. Magnetic labeling and cell sorting10.1016/0022-1759(84)90029-2 ↗
32. Determination of etoposide serum concentration in small pediatric samples by an improved method of reversed-phase high-performance liquid chromatography
33. In-vitro cytotoxic/cytostatic activity of anionic liposomes containing vinblastine against leukaemic human cell lines10.1211/0022357021778376 ↗
34. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide10.1016/S0378-4347(00)00586-7 ↗
35. New colorimetric cytotoxicity assay for anticancer-drug screening10.1093/jnci/82.13.1107 ↗
36. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting10.1007/s11095-006-9113-3 ↗
37. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines
38. Dissecting tumor pathophysiology using intravital microscopy10.1038/nrc778 ↗
39. Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field10.1515/znc-2000-3-422 ↗
40. Current treatment options for malignant melanoma10.2165/00003495-199855060-00006 ↗
41. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice
42. In vivo heating of magnetic nanoparticles in alternating magnetic field10.1118/1.1767101 ↗
43. Laser triggered drug release from magnetoliposomes10.1016/S0304-8853(98)00553-8 ↗
44. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy10.1016/S1567-5394(01)00171-2 ↗
45. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery10.1002/mrm.20074 ↗
46. Delivery of diagnostic agents for magnetic resonance imaging10.1016/S0169-409X(98)00103-3 ↗
47. Magnetoliposomes as contrast agents10.1016/S0076-6879(03)73012-2 ↗
48. Principles of magnetodynamic chemotherapy10.1016/j.mehy.2003.10.003 ↗
49. Vascular targeting of doxorubicin using cationic liposomes10.1016/j.ijpharm.2007.01.003 ↗
50. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies10.1006/phrs.2000.0714 ↗
51. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes10.1002/jps.1063 ↗
52. Cancer—an overview
53. Treatment of metastatic malignant melanoma10.1007/s11864-005-0002-5 ↗
54. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma10.1200/JCO.2005.04.5344 ↗
55. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation
56. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer10.1016/j.chemphyslip.2005.02.003 ↗
57. Biomimetic amplification of nanoparticle homing to tumors10.1073/pnas.0610298104 ↗
58. The role of iron in cancer
59. Iron as a potential co-factor in the pathogenesis of Kaposi's sarcoma?10.1002/(SICI)1097-0215(19981209)78:6<720::AID-IJC9>3.0.CO;2-F ↗
60. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy